BG
CELG

Bahl & Gaynor’s Celgene Corp CELG Stock Holding History

Bahl & Gaynor’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,360
Closed -$246K – 423
2017
Q4 		$246K Hold
2,360
– – ﹤0.01% 381
2017
Q3 		$344K Sell
2,360
-515
-18% -$70.1K ﹤0.01% 352
2017
Q2 		$373K Buy
2,875
+1,071
+59% +$131K ﹤0.01% 350
2017
Q1 		$224K Buy
+1,804
New +$216K ﹤0.01% 375

Other funds holding CELG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bahl & Gaynor's CELG Position: Q1 2018 in Review

Bahl & Gaynor sold out of Celgene Corp (CELG) in Q1 2018, closing a stake of 2,360 shares — an estimated $246K sold.

Bahl & Gaynor first reported a position in CELG in Q1 2017 and held it in 4 quarters. The position peaked at $373K in Q2 2017. 1,397 funds tracked by Wall St. Rank hold CELG as of Q1 2018.

  • Bahl & Gaynor reported no remaining Celgene Corp position as of Q1 2018 after selling out during the quarter.
  • Bahl & Gaynor sold 2,360 Celgene Corp shares in Q1 2018, an estimated $246K.
  • Bahl & Gaynor first reported a position in Celgene Corp in Q1 2017 and held it in 4 quarters.
  • Bahl & Gaynor's Celgene Corp position peaked at $373K in Q2 2017.
  • 1,397 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2018.

Based on Bahl & Gaynor's 13F filing for Q1 2018, filed 11 May 2018.